Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volume Control Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

NCT04722835
View directory record Official record
Conditions
Copd, Smoking, Tobacco Use
Interventions
Bronchoscopy with Bronchoalveolar Lavage (BAL)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis

NCT01394055
View directory record Official record
Conditions
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 28, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 12:56 AM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Not applicable Interventional

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

NCT01681225
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal-pressure guided mechanical ventilation, High PEEP mechanical ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
La Jolla, California • Stanford, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H7N7 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 28, 2026, 12:56 AM EDT
Not yet recruiting Not applicable Interventional

Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)

NCT07276555
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Functional Neurogenesis Stimulation Therapy, placebo control group
Device · Other
Lead sponsor
Neurocytonix, Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 28, 2026, 12:56 AM EDT
Enrolling by invitation Phase 4 Interventional

Pilot Study on EXPAREL as an Intra-articular Posteromedial Surgeon Administered (IPSA) Block vs. Local Infiltration Analgesia in Knee Replacement Surgery

NCT07584915
View directory record Official record
Conditions
Total Knee Arthroplasty, Total Knee Arthroplasty Recovery
Interventions
Intra-articular Posteromedial Surgeon Administered (IPSA) Block with LIA, Local Infiltration Analgesia (LIA), Bupivacaine liposome injectable suspension (IPSA block), Bupivacaine liposome injectable suspension (LIA)
Procedure · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mitigating the Disinhibiting Effects of Alcohol With Transcranial Magnetic Stimulation

NCT07188376
View directory record Official record
Conditions
Alcohol Risk Behaviors
Interventions
Intermittent Theta Burst Stimulation, Continuous Theta Burst Stimulation, Sham Transcranial Magnetic Stimulation
Device
Lead sponsor
Michael J. Wesley, PhD
Other
Eligibility
21 Years to 29 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 3 Interventional

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

NCT00952991
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
LAF237 = vildagliptin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 28, 2026, 12:56 AM EDT
Terminated Not applicable Interventional

Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room

NCT03938532
View directory record Official record
Conditions
Prematurity, BPD - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Newborn
Interventions
Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor, Tidal Volume Measurement using the Philips Respironics NM3 monitor
Device
Lead sponsor
Baystate Medical Center
Other
Eligibility
5 Minutes to 60 Minutes
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

NCT00224406
View directory record Official record
Conditions
Ischemia-Reperfusion Injury, Lung Transplantation
Interventions
Repertaxin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Micro and Macro Circulation in Sepsis

NCT05694455
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Starling Stroke Volume (Starling SV)- Passive Leg Raise, Microscan Sublingual Microscopy, Venous Excess Ultrasound Scoring (VExUS), Urine Collection
Diagnostic Test · Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 28, 2026, 12:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pathophysiology of Orthostatic Intolerance

NCT00608725
View directory record Official record
Conditions
Tachycardia, Postural Orthostatic Tachycardia Syndrome
Interventions
DAXOR, QSweat, Intrinsic Heart Rate
Radiation · Procedure · Drug
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 80 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional

Study of LJP 394 in Lupus Patients With History of Renal Disease

NCT00089804
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
12 Years to 70 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
32
States / cities
Birmingham, Alabama • Los Angeles, California • San Leandro, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2009 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117
View directory record Official record
Conditions
Acute Peripheral Arterial Occlusion
Interventions
Plasmin, Plasminogen Activator, Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

NCT04286789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control
Drug
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Los Angeles, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rivastigmine Study in Adolescents With Down Syndrome

NCT01084135
View directory record Official record
Conditions
Down Syndrome
Interventions
Rivastigmine, Liquid Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 28, 2026, 12:56 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

NCT05778188
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
Up to 10 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 12:56 AM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

NCT01286168
View directory record Official record
Conditions
Nonmalignant Breast Conditions, Breast Cancer
Interventions
Sodium hypochlorite (Dakin's Solution), Chlorhexidine gluconate disk, Control, Occlusive Adhesive Dressing
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 28, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

NCT04273217
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AV-1, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 28, 2026, 12:56 AM EDT